# Tolera Bio — Market Access & Reimbursement Strategy
*Confidential — for VC / VP discussion. Assumption-driven; to be firmed with a claims-based budget-impact model and lead-payer negotiation.*

---

## The objection, stated plainly

A durable, one-course therapy priced at ~$150k faces a structural payer problem that a chronic biologic does not:

**The wrong-pocket problem.** US commercial plan tenure averages ~3 years (job change, plan change, ACA churn). A payer that funds a one-time cure captures only the ~2–3 years of avoided cost before the patient — now in durable remission and cheap to insure — moves to a competitor's book. The savings become an externality the funding payer never collects. Break-even on the naïve 10-year framing (~3.8 years) is *longer than the payer holds the patient.*

This is exactly what rationed the Hepatitis C cures despite their being curative and cost-effective, and what has slowed gene-therapy uptake. A VC who has done healthcare will raise it. Our answer is not a louder cost-effectiveness claim — it is to change **whose** money is spent, **when**, and **how the contract is structured.**

---

## Four hooks that make a payer cover this

### 1. Front-load the offset — count acute care, not just biologics
The 10-year framing buries near-term wins. In the moderate–severe / biologic-eligible cohort, cost that lands **inside the current plan year** includes:
- Surveillance endoscopies with biopsy (~$2–5k each; several per year during monitoring)
- Esophageal dilations for stricturing disease
- **Food-impaction ER visits + endoscopic disimpaction** — acute, expensive, and the events patients fear most
- The biologic itself accruing at ~$40k/yr from month one

Halting progression compresses much of this into the first 12–24 months of avoided cost — not year 8. Counting acute-care + procedural offset (not biologic list price alone) raises the *effective* annual offset in the severe cohort and moves break-even toward or under the ~3-year tenure window.

### 2. Change the contract to track tenure — outcomes-based annuity
Instead of $150k upfront: ~$50k/yr for 3–4 years, **contingent on documented sustained remission** (histology / EREFS), capped at the headline value. Payment stops on relapse — a warranty. Because installments are tied to the patient's course, a payer funds them **only while it holds the patient.** Churn stops being catastrophic; each payer pays roughly in proportion to the tenure it gets. This also lowers first-year budget impact — what utilization-management committees actually optimize against. Precedent: gene-therapy annuity/outcomes deals (e.g., Zolgensma, Hemgenix installment and warranty structures).

### 3. Sequence go-to-market toward payers who internalize the full horizon
Land first where the wrong-pocket problem does not exist:
- **Integrated / capitated systems (Kaiser, VA, large IDNs)** — own both cost and downstream savings; a durable therapy is pure margin. Ideal first contracts.
- **Medicaid / CHIP and pediatric EoE** — long enrollment tenure and state-budget horizon; children treated early avoid *decades* of biologic exposure, feeding difficulty, and growth impact. Lifetime value is largest exactly where the payer horizon is longest. CMS access rails (Cell & Gene Therapy Access Model) support portability/reinsurance.
- **Self-insured employers** (most commercial lives) — internalize medical *plus* productivity (dysphagia, impaction anxiety, absenteeism); increasingly receptive to one-and-done therapies with administrative simplicity.

### 4. Name the problem in the pitch
The strongest slide *states* the wrong-pocket problem and shows a strategy for it. Demonstrating we've thought one level deeper than "it's cost-effective" is a credibility signal, not a weakness to hide.

---

## Three contracting models (carried into payer negotiation)

We deliberately do **not** pre-commit to one price architecture at Seed. All three remain open; we carry them into payer negotiation and finalize the structure with our lead payer partner — matched per channel (capitated vs. commercial vs. Medicaid):

| Model | Structure | What the payer gets | Trade-off |
|---|---|---|---|
| **Outcomes-based annuity** | ~$50k/yr × 3–4 yr, contingent on remission, capped ~$150k | Payment tracks tenure; neutralizes churn; lower first-year hit; warranty | Contracting complexity; needs remission tracking (our CDx provides it) |
| **One-time price + outcomes warranty** | ~$150k upfront + rebate if relapse in-window | Simple headline; warranty de-risks | Funding payer still fronts full cost; churn only partly solved |
| **Front-loaded value model** | ~$150k one-time; economics anchored on acute-care offset within tenure | Minimal model change; near-term offset math | Doesn't structurally solve churn; leans on budget-impact model |

**Why show the menu.** Pricing architecture for durable therapies is negotiated per-payer and per-channel; presenting the options with their trade-offs signals market-access sophistication and lets each payer segment (capitated vs. commercial vs. Medicaid) map to the structure that fits its horizon.

---

## The companion diagnostic is the enabler
Every model above except the simplest depends on **documenting sustained remission** to trigger, continue, or refund payment. Our blood-based companion diagnostic (trigger + clonotype assay) is the objective, low-cost remission monitor that makes outcomes-based contracting operable — a second reason the CDx is strategic, not just a patient-selection gate.

*All figures are Seed-stage planning assumptions grounded in public data; not guidance. A claims-based budget-impact and cost-effectiveness model is a funded post-Seed deliverable.*